Australians that are struggling to get a good night sleep can now screen their likelihood of suffering from sleep apnoea with medtech company ResApp Health (ASX: RAP) having launched their clinically tested SleepCheck app on the iPhone App Store.
By downloading the smartphone app, SleepCheck can record and analyse breaking and snorting sounds during sleep to provide an assessment of the likelihood the user suffers from sleep apnoea.
“We are excited to announce that SleepCheck is now available on the App Store. For the first-time, consumers have direct access to a clinical-grade, regulatory-approved screening tool for sleep apnoea,” said Resapp Managing Director, Tony Keating.
“Over a third of Australian adults do not get the duration or quality of sleep needed, which has major consequences for their health, safety and quality of life.
“Many adults snore, and loud snoring is an important indicator of sleep apnoea, although it often is ignored. SleepCheck offers an easy way to check if there’s more to your snore.”
Clinically tested through a 308 patient study, the SleepCheck algorithms provided an accurate assessment to identify obstructive sleep apnoea when compared to a simultaneous at-home comprehensive sleep study. With the trials validated, the software was approved in Europe to be CE Marked and in Australia by the Therapeutic Goods Association.
iPhone users can download the SleepCheck app for $7.99 (£4.99 in the UK) while ResApp expects it to make it available on Android devices later in the year.
Once the app collects sufficient data, users are provided with a low, medium, high or very high rating to classify their risk of having sleep apnoea and provided with recommended next steps.
Alongside SleepCheck, ResApp has another smartphone app for the diagnosis and management of respiratory diseases. To develop the project further, the Company has partnered with global health products manufacturer RB to build and test a prototype.
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
- Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
- Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
- ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
Leave a Comment
You must be logged in to post a comment.